Antibodies developed by researchers at Rensselaer Polytechnic Institute are unusually effective at preventing the formation of toxic protein particles linked to Alzheimer's disease and Parkinson's disease, as well as Type 2 diabetes, according to a new study.
The onset of these devastating diseases is associated with the inappropriate clumping of proteins into particles that are harmful to cells in the brain (Alzheimer's disease and Parkinson's disease) and pancreas (Type 2 diabetes). Antibodies, which are commonly used by the immune system to target foreign invaders such as bacteria and viruses, are promising weapons for preventing the formation of toxic protein particles. A limitation of conventional antibodies, however, is that high concentrations are required to completely inhibit the formation of toxic protein particles in Alzheimer's, Parkinson's, and other disorders.
To address this limitation, a team of researchers led by Rensselaer Professor Peter Tessier has developed a new process for creating antibodies that potently inhibit formation of toxic protein particles. Conventional antibodies typically bind to one or two target proteins per antibody. Antibodies created using Tessier's method, however, bind to 10 proteins per antibody. The increased potency enables the novel antibodies to prevent the formation of toxic protein particles at unusually low concentrations. This is an important step toward creating new therapeutic molecules for preventing diseases such as Alzheimer's and Parkinson's.
"It is extremely difficult to get antibodies into the brain. Less than 5 percent of an injection of antibodies into a patient's blood stream will enter the brain. Therefore, we need to make antibodies as potent as possible so the small fraction that does enter the brain will completely prevent formation of toxic protein particles linked to Alzheimer's and Parkinson's disease," said Tessier, assistant professor in the Howard P. Isermann Department of Chemical and Biological Engineering at Rensselaer. "Our strategy for designing antibody inhibitors exploits the same molecular interactions that cause toxic particle formation, and the resulting antibodies are more potent inhibitors than antibodies generated by the immune system."
Results of the new study, titled "Rational design of potent domain antibody inhibitors of amyloid fibril assembly," were published online last week by the journal Proceedings of the National Academy of Sciences (PNAS). The study may be viewed at: http://www.pnas.org/content/early/2012/11/14/1208797109.abstract
Rensselaer Polytechnic Institute: http://www.rpi.edu/News
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Genetic study could provide hope for men with advanced forms of the disease with findings that could lead to personalised treatments
The agency that administers Obamacare in California moved to make expensive medicines more affordable in 2016. In most plans, patients will pay no more than $150 or $250 a month.
When former prisoners flock together, more land back in jail
Avian influenza is ravaging poultry flocks across the Upper Midwest. The virus is "doing things we've never seen it do before," and understanding about transmission is very limited, a scientist says.
Youthful blood has once again shown its promise as an elixir of youth – this time helping to rejuvenate bones. But exactly how it does so is still to be unravelled
LONDON (Reuters) - Victims of childhood bullying are more likely to be overweight or obese as adults and have a higher risk of developing heart disease, diabetes and other illnesses, according to a study by British psychiatrists.
Study finds nixing phones is equivalent to adding an hour of learning to the school week, or five days to the school year
Drug-resistant tuberculosis is a growing problem. It's spread through the air. It can kill you. And it's incredibly difficult to treat. But a program in Peru shows that the disease can be cured.
Scientists have diagnosed strain of leprosy on man from Scandinavia who died in Essex in the fifth or early sixth century
Legalization keeps rolling ahead. But because of years of government roadblocks on research, we don’t know nearly enough about the dangers of marijuana—or the benefits